Business
NeoGenomics and Bayer Collaborate to Offer NTRK Testing for Certain Colorectal and Thyroid Cancer Patients
FT. MYERS, FL / ACCESSWIRE / May 5, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced a
About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / May 5, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced a collaboration with Bayer (BAYN) to facilitate an RNA-based Neurotrophic Tropomyosin-Receptor Kinase (NTRK) testing for certain colorectal and thyroid cancer patients. All eligible patients who enroll and opt-in to a Sponsored Testing Program will receive testing at no cost to themselves or their insurance. Bayer will cover the total cost of this test regardless of the results and treatment decision.The Sponsored Testing Program is for metastatic colorectal cancer (mCRC) patients with high Microsatellite Instability (MSI-H) status or deficient DNA mismatch repair (MMR-), as well as patients with radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). All eligible patients who enroll in the Sponsored Testing Program will receive an RNA-based next-generation sequencing (NGS) test (NTRK NGS Fusion Profile) from NeoGenomics and patients will also receive a NeoGenomics Pan-Tropomyosin receptor kinase (TrK) Immunohistochemistry (IHC) test. For more information onthe Sponsored Testing Program and its no-cost testing, or to download the Test Request Form, healthcare professionals should visit https://www.neogenomics.com/ntrk-sponsored-testing-program.A higher prevalence of NTRK gene fusions are found among patients with metastatic colorectal cancer (mCRC) with prior high microsatellite instability (MSI-H) status. Studies suggest NTRK gene fusions are greater than 3% among these patients. NTRK rearrangements are also found to occur in 2.4-12% of radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC) patients with less favorable disease outcomes. Genomic cancer tests that detect an NTRK gene fusion provide actionable information for patients that harbor the genomic alteration and may be appropriate for therapy.\"Our collaboration with Bayer to provide eligible colorectal and thyroid cancer patients with no-cost testing for NTRK gene fusions will help facilitate critical therapy for these patients,\" said Douglas M. VanOort, NeoGenomics' Chairman and CEO. \"As a leading provider of oncology testing for clinical trials and patient care, NeoGenomics is in a unique position to provide access to genomic tests enabling patients to access important therapi...